PTC could receive an additional $1.6 million based on achievement of certain milestones.
PTC Therapeutics and the Spinal Muscular Atrophy Foundation agreed to expand their research collaboration to identify and characterized compounds to treat the disease.
PTC will receive an additional $1.6 million in funding when certain milestone considerations are met.
The partnerhip is focusing on candidates to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein, the absence of which causes SMA.
“By applying our proprietary technologies,” says Stuart W. Peltz, Ph.D., president and CEO of PTC, “we have made important progress in our efforts to identify treatments for SMA.”
